Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States
- 1 November 2025
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (5) , 1028-1035
Abstract
Background Second-generation androgen receptor pathway inhibitors (ARPIs) have transformed treatment for patients with advanced prostate cancer. Despite overlapping indications and comparable efficacy among these ARPIs, their staggered market entry and differing toxicity profiles may influence real-world prescribing. We characterized temporal trends and utilization patterns of these agents as frontline treatment for advanced prostate cancer in the United States. Methods Using the Merative MarketScan database, we identified patients with prostate cancer receiving enzalutamide, apalutamide, or darolutamide between 2012 and 2023. ARPI therapy was classified as first-line if initiated after ≥180 days of continuous enrollment. Annual proportions of first-line initiation and overall utilization of ARPIs were assessed descriptively. Comparisons by geographic status, urbanicity, insurance plan, and metastatic status were evaluated using chi-squared testing and multivariable modeling. Results Among 1.1 million individuals with prostate cancer, 3773 patients received ARPI therapy, of whom 1914 met criteria for first-line analysis. Use of first-line darolutamide steadily increased, rising to 42% in 2023 and surpassing enzalutamide. First-line ARPI selection did not differ significantly by region, urbanicity, insurance, or metastatic status. Overall ARPI utilization increased 21-fold over the study period, with enzalutamide remaining the most common agent. In 2023, a higher proportion of darolutamide fills occurred in metropolitan areas (p = 0.0008), and among metastatic patients (p = 0.0058). Conclusion Darolutamide rapidly emerged as the most selected first-line ARPI by 2023, without consistently observed differences by patient demographics. However, continued dominance of enzalutamide for overall fills may highlight durability of legacy therapy, particularly among non-metropolitan and non-metastatic populations.Keywords
This publication has 30 references indexed in Scilit:
- Prostate CancerJAMA, 2025
- Government Funding for the Development of EnzalutamideJAMA Oncology, 2025
- Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate CancerJAMA Network Open, 2024
- Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS StudyEuropean Urology, 2024
- Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover TrialTargeted Oncology, 2023
- Adoption of Innovative Therapies Across Oncology Practices—Evidence From ImmunotherapyJAMA Oncology, 2023
- Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyThe Lancet Oncology, 2021
- Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor InhibitorsJAMA Network Open, 2020
- Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysisInternational Journal of Clinical Oncology, 2020
- Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER‐Medicare investigationCancer Medicine, 2019